No Data
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week
Express News | Cellectis Shares Are Trading Higher After the Company Announced the FDA Granted Orphan Drug and Rare Pediatric Designation Disease to UCART22
Cellectis Gains FDA Designations for Leukemia Therapy
Express News | Cellectis Announces FDA Grants Orphan Drug And Rare Pediatric Disease Designation To UCART22 For Acute Lymphoblastic Leukemia Treatment; ALL Represents 10% Of U.S. Leukemia Cases And Progresses Rapidly
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 Product Candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
No Data
73960874 : Not moving
Jaguar8 OP 73960874 : It’s AM so won’t get much traction esp its a huge float. Tomorrow likely will get attention
73960874 Jaguar8 OP : Thanks, I’m already in $2.63 so feeling Sad
annna 73960874 : same, my cost is 2.6![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jaguar8 OP 73960874 : Don’t cry
View more comments...